The IIH Pressure Trial was a single United Kingdom centre, double-masked, randomised and placebo-controlled trial. It evaluated the use of subcutaneous exenatide, a glucagon-like peptide 1 receptor agonist, and placebo in women with papilloedema secondary to active IIH, with the primary end point at 12 weeks [1]. The trial was a landmark publication as it deployed highly accurate telemetric ICP devices [2]. The intracranial pressure was significantly reduced at all time points in the intervention arm as compared to placebo, independent of weight change.
References
Mitchell JL, Lyons HS, Walker JK, Yiangou A, Grech O, Alimajstorovic Z, et al. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain. 2023;146:1821–30. https://doi.org/10.1093/brain/awad003.
Mollan SP, Momin SNA, Khatkar PS, Grech O, Sinclair AJ, Tsermoulas G. A Neuro-Ophthalmologist’s Guide to Advances in Intracranial Pressure Measurements. Eye Brain. 2023;15:113–24. https://doi.org/10.2147/EB.S404642.
Funding
AS is supported by a Sir Jules Thorn Award for Biomedical Research. This trial was funded by Enterprising Birmingham, University of Birmingham, UK, from 1 August 2016. Further funding was sought and from 1 August 2019 an investigator led grant was obtained from Invex Therapeutics.
Author information
Authors and Affiliations
Contributions
Design and drafting – GB, ML. Review – GT, AJS, SPM. All authors approved the final version.
Corresponding author
Ethics declarations
Competing interests
SM reports consultancy fees (Invex Therapeutics); advisory board fees (Ocular therapeutix); speaker fees (Teva); Travel (AbbVie and European Alliance of Associations for Rheumatology); Receipt of equipment (Heidelberg Engineering). SM is a section editor at Eye Journal. AS reports consultancy fees from Novartis, AbbVie, Vertex and Orion Pharma and speaker fees from Teva UK and Novartis. She was previously a Director and Chief Scientific Officer with shares at Invex Therapeutics. Authors declare no other financial relationships with any organisations that might have an interest in the submitted work; and no other relationships or activities that could appear to have influenced the submitted work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Berman, G., Lowe, M., Tsermoulas, G. et al. Infographic: Landmark trials in Neuro-Ophthalmology—results of the phase II Idiopathic Intracranial Hypertension Pressure Trial. Eye (2025). https://doi.org/10.1038/s41433-025-03918-8
Received:
Revised:
Accepted:
Published:
Version of record:
DOI: https://doi.org/10.1038/s41433-025-03918-8
